Regulation of apoptosis in uterine leiomyomata

Endocrinology

Volumn 138, Issue 7, 1997, Pages 3056-3064

  Burroughs, Kevin D ^a   Kiguchi, Kaoru ^b   Howe, Susan R ^a   Fuchs Young, Robin ^b   Trono, David ^b   Carl Barrett, J ^a   Walker, Cheryl ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FULVESTRANT; TAMOXIFEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HORMONAL REGULATION; LEIOMYOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; UTERUS FUNCTION;

EID: 0030921498     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.138.7.5273     Document Type: Article

References (53)

1. Kyprianou N, English HF, Davidson NE, Isaacs JT 1991 Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166
2. Kyprianou N, English HF, Isaacs JT 1990 Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753
3. Wärri AM, Huovinen RL, Laine AM, Martikainen PM, Härkönen PL 1993 Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vim and in vitro. }Natl Cancer Inst 85:1412-1418
4. Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, Knight RA 1995 Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 96:141-145
5. Perry RR, Kang Y, Greaves B 1995 Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238-245
6. Buttram Jr VC, Reiter RC 1981 Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 36:433-445
7. Clark BF 1971 The effects of oestrogen and progesterone on uterine cell division and epithelial morphology in spayed, adrenalectomized rats. J Endocrinol 50:527-528
8. Tachi C, Tachi S, Lindner HR1972 Modification by progesterone of oestradiolinduced cell proliferation, RNA synthesis and oestradiol distribution in the rat uterus. J Reprod Fertil 31:59-76
9. Witherspoon JT1935 The hormonal origin of uterine fibroids: an hypothesis. Am J Cancer 24:402-406
10. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT 1986 Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J 293:339-362
11. Wilson EA, Yang F, Rees ED 1980 Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 55:20-24
12. Sadan O, Van Iddekinge B, Van Gelderen CJ, Savage N, Becker PJ, Van Der Walt LA, Robinson M 1987 Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 24:263-267
13. Marelli G, Codegoni AM, Bizzi A 1989 Estrogen and progesterone receptors in leiomyomas and normal uterine tissues during reproductive life. Acta Eur Fertil 20:19-22
14. Follow K, Sinnecker G, Boquoi E, Follow B 1978 In vitro conversion of estradiol-17β into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem 16:493-502
15. Verkauf BS 1993 Changing trends in treatment of leiomyomata uteri. Curr Opin Obstet Gynecol 5:301-310
16. Corbin A, Beattie CW 1975 Inhibition of the pre-ovulatory proestrous gonadotropin surge, ovulation, and pregnancy with a peptide analogue of luteinizing hormone releasing hormone. Endocr Res Commun 2:1-23
17. Rabin D, McNeil LW 1980 Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J Clin Endocrinol Metab 51:873-876
18. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C 1988 The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67:701-706
19. Dawood MY, Lewis V, Ramos J 1989 Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 52:21-26
20. Friedman AJ, Hanison-Atlas D, Barbieri RL, Benacerraf B, Gleason R, Schiff 11989 A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 51:251-256
21. Friedman AJ, Rein MS, Harrison-Atlas D, Garfield JM, Doubilet PM 1989 A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 52:728-733
22. Adamson GD 1992 Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 166:746-751
23. Benagiano G, Morini A, Primiero FM 1992 Fibroids: overview of current and future treatment options. Br J Obstet Gynaecol [Suppl 7] 99:18-22
24. Donnez J, NisoIIe M, Grandjean P, Gillerot S, Clerckx F 1992 The place of GnRH agonists in the treatment of endometriosis and fibroids by advanced endoscopie techniques. Br J Obstet Gynaecol [Suppl 7] 99:31-33
25. Even JI, Wolf DC, Howe SR, Goldsworthy TL, Walker C1995 Rodent model of reproductive tract leiomyomata: clinical and pathological features. Am J Pathol 146:1556-1567
26. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C 1995 Rodent model of reproductive tract leiomyomata: establishment and characterization of tumor-derived cell lines. Am J Pathol 146:1568-1579
27. Furr BJA, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205
28. Pasqualini JR, Sumida C, Giambiagi N 1988 Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem 31:613-643
29. Howe SR, Gottardis MM, Everitt JI, Walker C 1995 Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in i'itro and in vivo. Endocrinology 136:4996-5003
30. Gavrieli Y, Sherman Y, Ben-Sasson SA 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
31. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H 1994 Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71:219-225
32. Wilson JW, Wakeling AE, Morris ID, Hickman JA, Dive C 1995 MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormonewithdrawal and DNA damage. Int J Cancer 61:502-508
33. Reddel RR, Murphy LC, Sutherland RL 1984 Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res 44:2398-2405
34. Chouvet C, Vicard E, Frappart L, Palette N, Lefebvre MF, Saez S1988 Growth inhibitory effect of 4-hydroxy-tamoxifen on the BT-20 mammary cancer cell line. J Steroid Biochem 31:655-663
35. Grenman S, Shapira A, Carey TE 1988 In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. Gynecol Oncol 30:228-238
36. Howe SR, Pass HI, Ethier SP, Matthews WJ, Walker C 1996 Presence of an IGF-I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Cancer Res 56:4049-4055
37. Kon OL 1983 An antiestrogon-binding protein in human tissues. J Biol Chem 253:3173-3177
38. Sudo K, Monsma Jr FJ, Katzenellenbogen BS1983 Anticstrogen binding sites distinct from the cstrogen receptor: subcellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology 112:425-434
39. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA 1993 Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992-998
40. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla GK 1994 The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol 48:481-486
41. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C 1996 Inhibition of cstrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinogenesis 17:151-159
42. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutqvist LE, Glas U, Silfverswärd C, Somell A, Wilking N, Hjalmar M 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-120
43. Andersson M, Storm HH, Mouridsen HT 1991 Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013-1017
44. Fisher B, Coslantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537
45. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC 1991 Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43
46. Patterson JS 1981 Clinical aspects and development of antioestrogcn therapy: a review of the endocrine effect of tamoxifen in animals and man. J Endocrinol 89:67P-75P
47. Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
48. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular domains. Mol Endocrinol 8:21-30
49. Hendrickson MR, Kempson RL 1980 The normal myometrium. In: Bennington JL (ed) Surgical Pathology of the Uterine Corpus. Saunders, Philidelphia, pp 439-451
50. Friedman AJ, Lobel SM, Rein MS, Barbieri RL 1990 Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropinrelcasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 163:1114-1119
51. Cohen D, Mazur MT, Jozefczyk MA, Badawy SZA 1994 Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy. J Reprod Med 194:377-380
52. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, et al. 1994 Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
53. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU 1995 Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sei 761:355-360